<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04416204</url>
  </required_header>
  <id_info>
    <org_study_id>22074</org_study_id>
    <nct_id>NCT04416204</nct_id>
  </id_info>
  <brief_title>Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes</brief_title>
  <official_title>Role of Hepatic Glycogen on Nocturnal EGP in T2D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our experimental approach in this study intends to investigate the role of hepatic glycogen
      content on nocturnal regulation of endogenous glucose production including the relative
      contributions of glycogenolysis and gluconeogenesis and the extent to which this differs
      between subjects with type 2 diabetes and subjects without diabetes. Both participants with
      type 2 diabetes and participants without diabetes will be studied after consuming either a
      low carbohydrate (no glycogen loading) or high carbohydrate (glycogen loading) diet.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates and contribution of gluconeogenesis to nocturnal endogenous glucose production is lower with glycogen loading than without in type 2 diabetes.</measure>
    <time_frame>Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks</time_frame>
    <description>We will accept this hypothesis if rates and contribution of gluconeogenesis to nocturnal endogenous glucose production is lower in type 2 diabetes with glycogen loading than without</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates and contribution of glycogenolysis to nocturnal endogenous glucose production is higher with glycogen loading than without, in type 2 diabetes.</measure>
    <time_frame>Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks</time_frame>
    <description>We will accept this hypothesis if the rates and contribution of glycogenolysis to nocturnal endogenous glucose production is higher with glycogen loading than without in type 2 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of gluconeogenesis through the night is lower with glycogen loading than without in participants without diabetes.</measure>
    <time_frame>Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks</time_frame>
    <description>We will accept this hypothesis if rates of gluconeogenesis are lower with glycogen loading than without in participants without diabetes as well.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants without diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Carbohydrate (glycogen loading)</intervention_name>
    <description>Subjects will consume an isocaloric diet [60% carbs, 20% protein, 20% fat (33 kcal/kg/day)] for 3 days prior to the overnight study.</description>
    <arm_group_label>Participants without diabetes</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low carbohydrate (No Glycogen Loading)</intervention_name>
    <description>Subjects will consume an isocaloric diet [40% carbs, 20% protein, 40% fat (33 kcal/kg/day)] for 3 days prior to the overnight study.</description>
    <arm_group_label>Participants without diabetes</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-75

          -  BMI 27-40kg/m^2

          -  Participants with type 2 diabetes:

               -  HbA1c less than or equal to 8.5% on lifestyle therapy or monotherapy with
                  metformin or sulphonylureas (SU); or less than or equal to 7.5% on two oral
                  hypoglycemic agents (Metformin and SU)

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  Morbidities precluding participation

          -  Participants with type 2 diabetes:

               -  Therapy with insulin

               -  SGLT2 inhibitors

               -  GLP-1 based approaches

               -  TZDs

               -  Unstable diabetic retinopathy

               -  Microalbuminuria

               -  Macrovascular disease

               -  Medications affecting GI motility (eg., erythromycin, pramlintide)

               -  Upper GI disorder/surgery

          -  Participants without diabetes:

               -  Medications (except stable thyroid hormone or hormone replacement therapy) that
                  could influence glucose tolerance

               -  History of diabetes mellitus in first degree family members or prior history of
                  diabetes mellitus or gestational diabetes, or pre-diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandra Weaver</last_name>
    <phone>434-924-3512</phone>
    <email>acw6qc@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Rita Basu, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>hepatic glycogen</keyword>
  <keyword>endogenous glucose production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

